Table 3.
Duration of ADT Use and Selected Outcomes
| Variable | Myocardial Infarction
|
Sudden Cardiac Death
|
Diabetes
|
Fragility Fracture
|
||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| Duration of ADT use, months | ||||||||
| < 3 | Referent | Referent | Referent | Referent | ||||
| 3–6 | 0.99 | 0.88 to 1.12 | 0.95 | 0.79 to 1.14 | 1.00 | 0.90 to 1.10 | 0.96 | 0.87 to 1.05 |
| 6–24 | 0.92 | 0.83 to 1.03 | 1.00 | 0.85 to 1.17 | 0.99 | 0.90 to 1.08 | 1.11 | 1.03 to 1.21 |
| > 24 | 0.93 | 0.84 to 1.04 | 0.81 | 0.69 to 0.96 | 1.09 | 0.99 to 1.19* | 1.21 | 1.11 to 1.31 |
|
| ||||||||
| Duration of ADT use per month of ADT | 0.999 | 0.998 to 1.001 | 0.998 | 0.997 to 1.000 | 1.001 | 1.000 to 1.001 | 1.002 | 1.001 to 1.003 |
|
| ||||||||
| P value | .30 | .0408 | .26 | < .0001 | ||||
NOTE. Primary outcomes were estimated using multivariable Cox proportional hazards models. Androgen deprivation therapy (ADT) was modeled as both a categorical variable and a continuous variable. All models were also adjusted for age, comorbidity, medication use, income quintile, primary care access, and rurality. Values in bold type are statistically significant at P < .05. P values refer to models containing duration of ADT use as a continuous variable.
Abbreviations: ADT, androgen deprivation therapy; HR, hazard ratio.
*
P = .079.